Table 3.
Assessment | Infection marker | N | Trial arm | Unadjusted | Adjusteda | ||||
---|---|---|---|---|---|---|---|---|---|
Iron (%) | Control (%) | RR (95% CI) | P valueb | Nc | RR (95% CI) | P valuec | |||
Pregnant | Bacterial vaginosisd | 298 | 0.776 | 245 | 0.704 | ||||
ANC1 | Nugent 7–10e | 298 | 12/152 (7.9) | 9/146 (6.2) | 1.28 (0.56–2.95) | 0.653 | 245 | 0.93 (0.33–2.56) | 0.881 |
N = 315 | Nugent 4–6e | 298 | 17/152 (11.2) | 19/146 (13.0) | 0.86 (0.47–1.59) | 0.723 | 245 | 0.94 (0.47–1.88) | 0.858 |
Nugent 0–3e | 298 | 123/152 (80.9) | 118/146 (80.8) | 1.00 (0.90–1.12) | 1 | 245 | 1.03 (0.91–1.15) | 0.665 | |
T. vaginalis f | 286 | 23/147 (15.6) | 14/139 (10.1) | 1.55 (0.83–2.90) | 0.217 | 286 | 1.55 (0.83–2.90) | 0.168 | |
Vaginal discharge | 315 | 14/163 (8.6) | 12/152 (7.9) | 1.09 (0.52–2.28) | 0.841 | 315 | 1.08 (0.51–2.25) | 0.846 | |
pH ≥ 4.5 | 309 | 92/158 (58.2) | 86/151 (57.0) | 1.02 (0.84–1.24) | 0.908 | 260 | 1.06 (0.86–1.31) | 0.555 | |
Non-pregnant | Bacterial vaginosisd | 671 | 0.588 | 546 | 0.676 | ||||
FINf | Nugent 7–10e | 671 | 46/341 (13.5) | 40/330 (12.1) | 1.11 (0.75–1.65) | 0.645 | 546 | 0.86 (0.56–1.34) | 0.509 |
N = 877 | Nugent 4–6e | 671 | 35/341 (10.3) | 26/330 (7.9) | 1.30 (0.80–2.11) | 0.347 | 546 | 1.21 (0.72–2.03) | 0.467 |
Nugent 0–3e | 671 | 260/341 (76.2) | 264/330 (80.0) | 0.95 (0.88–1.03) | 0.263 | 546 | 0.99 (0.90–1.08) | 0.806 | |
T. vaginalis f | 716 | 20/360 (5.6) | 15/356 (4.2) | 1.32 (0.69–2.53) | 0.489 | 716 | 1.30 (0.67–2.50) | 0.432 | |
Vaginal discharge | 874 | 49/425 (11.5) | 31/449 (6.9) | 1.67 (1.09–2.57) | 0.019 | 874 | 1.63 (1.06–2.51) | 0.026 |
aAdjusted for baseline infection and use of antibiotics in previous 3 months
bFishers exact test
cLogistic regression
dEach group compared to both other groups
eExcludes those less than 6 months post menarcheal
fBaseline not available